Pedro Armarioa, Carlos Brotonsb, Roberto Elosuac, María Alonso de Leciñanad, Almudena Castroe, Albert Claràf, Olga Cortésg, Ángel Díaz Rodríguezh, María Herranzi, Soledad Justoj, Carlos Lahozk, Juan Pedro Botetl, Antonio Pérez Pérezm, Rafael Santamarían, Ricard Tresserraso, Susana Aznar Lainp, Miguel Ángel Royo Bordonadaq
aSociedad Española-Liga Española para la Lucha contra la Hipertensión Arterial .
bSociedad Española de Medicina Familiar y Comunitaria (SemFYC) .
cSociedad Española de Epidemiología (SEE).
dSociedad Española de Neurología (SEN) .
eSociedad Española de CardiologíaeSociedad Española de Cardiología-Coordinadora Nacional Sección de Prevención.
fSociedad Española de Angiología y Cirugía Vascular .
gAsociación Española Pediatría de Atención Primaria (AEPap).
hSociedad Española de Médicos de Atención Primaria (Semergen) .
iFederación de Asociaciones de Enfermería Comunitaria y Atención Primaria (FAECAP).
jMinisterio de Sanidad, Consumo y Bienestar Social. España .
kSociedad Española de Medicina Interna (SEMI) .
lSociedad Española de Arteriosclerosis .
mSociedad Española de Diabetes . Madrid. España.
nSociedad Española de Nefrología .
oSociedad Española de Salud Pública y Administración Sanitaria (SESPAS).
pFacultad de Ciencias del Deporte. Universidad Castilla La Mancha. Toledo. Grupo de Investigación PAFS (Promoción de la Actividad Física para la Salud).
qInstituto de Salud Carlos III. Madrid. España.
Correspondence: P Armario. E-mail: parmario@csi.cat
Reference of this article: Armario P, Brotons C, Elosua R, Alonso de Leciñana M, Castro A, Clarà A, et al. Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines. Rev Pediatr Aten Primaria. 2020;22:e153-e185.
Published in Internet: 14-12-2020 - Visits: 8972
Abstract
We present the adaptation for Spain of the updated European Cardiovascular Prevention Guidelines. In this update, greater stress is laid on the population approach, and especially on the promotion of physical activity and healthy diet through dietary, leisure and active transport policies in Spain. To estimate vascular risk, note should be made of the importance of recalibrating the tables used, by adapting them to population shifts in the prevalence of risk factors and incidence of vascular diseases, with particular attention to the role of chronic kidney disease. At an individual level, the key element is personalized support for changes in behaviour, adherence to medication in high-risk individuals and patients with vascular disease, the fostering of physical activity, and cessation of smoking habit. Furthermore, recent clinical trials with PCSK9 inhibitors are reviewed, along with the need to simplify pharmacological treatment of arterial hypertension to improve control and adherence to treatment. In the case of patients with type 2 diabetes mellitus and vascular disease or high vascular disease risk, when lifestyle changes and metformin are inadequate, the use of drugs with proven vascular benefit should be prioritised. Lastly, guidelines on peripheral arterial disease and other specific diseases are included, as it is recommended no to prescribe antiaggregants in primary prevention.
Keywords
● Arterial hypertension ● Clinical practice guidelines ● Diabetes ● Healthy diet ● Prevention and control ● Smoking ● Vascular diseases
Comments
This article has no comments yet.